Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13–26 years) enrolled in the VALHIDATE study

HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the mai...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Hum Vaccin Immunother
Päätekijät: Orlando, Giovanna, Fasolo, Michela, Mazza, Francesca, Ricci, Elena, Esposito, Susanna, Frati, Elena, Zuccotti, Gian Vincenzo, Cetin, Irene, Gramegna, Maria, Rizzardini, Giuliano, Tanzi, Elisabetta, group, VALHIDATE study
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2014
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896517/
https://ncbi.nlm.nih.gov/pubmed/24423757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.27682
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia